Compare Quest Diagnostics Inc (DGX) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Live Nation Entertainment, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.98 (market cap $26.21B), while Live Nation Entertainment, Inc. trades at $184.72 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| DGX | LYV | |
|---|---|---|
Market Cap | $26.21B | $42.71B |
Sector | Health | Industrials |
52-Week High | $238.50 | $186.59 |
52-Week Low | $173.49 | $125.61 |
Enterprise Value | $31.97B | $44.92B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
LYV trades at $184.64, up 2.2% on the day, with a bullish technical signal from moving averages and strong analyst support (86.96% buy ratings). The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by record concert demand. However, valuation metrics like a P/E of 117.49 and negative ROE of -116.65% highlight significant premium pricing and profitability challenges.
Outlook remains positive due to robust live event demand and raised full-year expectations, but risks include high debt, legal uncertainties, and margin pressure. The consensus price target of $209.54 suggests ~13.5% upside, though investors should weigh growth potential against elevated valuation and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
